Atai Life Sciences N.V.
1.33
-0.09 (-6.34%)
At close: Jan 14, 2025, 3:59 PM
1.33
0.02%
After-hours Jan 14, 2025, 07:59 PM EST
undefined%
Bid 1.32
Market Cap 223.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.8
PE Ratio (ttm) -1.66
Forward PE n/a
Analyst Buy
Ask 1.33
Volume 1,263,111
Avg. Volume (20D) 1,711,508
Open 1.43
Previous Close 1.42
Day's Range 1.30 - 1.43
52-Week Range 1.03 - 2.85
Beta undefined

About ATAI

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 83
Stock Exchange NASDAQ
Ticker Symbol ATAI

Analyst Forecast

According to 4 analyst ratings, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 652.05% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Atai Life Sciences N.V. is scheduled to release its earnings on Mar 27, 2025, before market opens.
Analysts project revenue of $250.00K, reflecting a 1.29K% YoY growth and earnings per share of -0.15, making a 25.00% increase YoY.
7 months ago · Source
-8.44%
Shares of psychedelics companies are trading lower... Unlock content with Pro Subscription
9 months ago · Source
+27.81%
ATAI Life Sciences shares are trading higher after Maxim Group upgraded the stock from Hold to Buy and announced a $6 price target.